Phaseline

Companies › Vantive Health

Vantive Health: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Genitourinary; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Prismocitrate 18
Citrate-based anticoagulant for regional citrate anticoagulation (RCA) in extracorporeal c
–Phase 3Regional Citrate Anticoagulation (RCA)Jan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05399537Prismocitrate 18Phase 3Regional Citrate Anticoagulation (RCA)GenitourinaryJan 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Fertility Center of Las Vegas Zydus Lifesciences Granata Bio Dimerix Bioscience Chengdu Qingshan Likang Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.